Optimal treatments in cost-effectiveness analysis in the presence of covariates: improving patient subgroup definition

DOI10.1016/J.EJOR.2012.11.003MaRDI QIDQ2253554zbMATH OpenOpenAlexFDO

Authors Yanyan Li

Publication date 27 July 2014

Published in European Journal of Operational Research (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1016/j.ejor.2012.11.003

zbMATH Keywords

subgroup analysisintrinsic priorsBayesian variable selectionutility functioncost-effectiveness analysisbivariate regression model

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Optimal healthcare decisions: the importance of the covariates in cost-effectiveness analysis
• Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective
• Subgroup identification and variable selection for treatment decision making
• Covariate-adjusted cost-effectiveness ratios
• A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects
• Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment
• Incorporating patients' characteristics in cost-effectiveness studies with clinical trial data: a flexible Bayesian approach
• Optimal Allocation to Treatment Groups under Variance Heterogeneity
• A general statistical framework for subgroup identification and comparative treatment scoring
• Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness

Cited in

(8)

• Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment
• Optimal healthcare decisions: comparing medical treatments on a cost-effectiveness basis
• Incorporating patients' characteristics in cost-effectiveness studies with clinical trial data: a flexible Bayesian approach
• Optimal healthcare decisions: the importance of the covariates in cost-effectiveness analysis
• Covariate-adjusted cost-effectiveness ratios
• Dynamic cost-benefit analysis of drug substitution programs
• Cost-effectiveness analysis for heterogeneous samples
• Case-Only Analysis of Treatment-Covariate Interactions in Clinical Trials

This page was built for publication: Optimal treatments in cost-effectiveness analysis in the presence of covariates: improving patient subgroup definition

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2253554)